Clinical data disclosed in November 2025 to be presented at medical meeting with new supportive translational data for both programsVispa-cel ...
Cellares has joined forces with the Stanford Center for Definitive and Curative Medicine (CDCM) and Stanford Innovative ...
While interested in CAR-T therapies’ potential to achieve durable, drug-free remission in serious autoimmune conditions, the ...
WuXi Biologics (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has signed a license and research ...
Moderna’s Chief Medical Officer Jacqueline Miller, M.D., is stepping down after a little more than a year in the role. | Moderna’s Chief Medical Officer Jacqueline Miller, M.D., is stepping down after ...
Kyowa Kirin affirms commitment to developing rocatinlimab as a life-changing differentiated asset with significant market ...
Moderna, Inc. (NASDAQ:MRNA) today announced that David Berman, M.D., Ph.D. has been appointed as the Company's Chief ...
The FDA has granted fast track designation (FTD) to LBL-034, an investigational GPRC5D/CD3 bispecific T-cell engager (BiTE), for patients with relapsed/refractory multiple myeloma (R/R MM).
Under the terms of the agreement, Repertoire will receive an upfront payment of $85 million and up to an additional $1.84 billion for achieving certain development and commercial milestones, as well ...
Tevogen Bio, the company’s lead initiative, has completed a proof-of-concept clinical trial demonstrating the potential of its single-HLA-restricted, genetically unmodified allogeneic T cells. The ...
Drugmaker Eli Lilly is partnering with Repertoire Immune Medicines in a deal worth up to $1.93 billion to develop therapies ...
The FDA's breakthrough therapy designation facilitates accelerated development and regulatory review for therapies showing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results